论著

18 **q**-甘草酸二铵与格列本脲联用对实验性糖尿病大鼠糖代谢的影响及其机制

陈洁,彭仁琇*,杨静,吕靖峰

(武汉大学医学院药理学系, 湖北 武汉 430071)

收稿日期 2005-2-4 修回日期 网络版发布日期 2008-8-11 接受日期 2005-4-18

摘要 目的 探讨 $18~\alpha$ -甘草酸二铵 (DG)是否影响格列本脲 (G1i) 的代谢及降糖效应,联用的效应及其机制。方法观察DG (25 mg \cdot kg $^{-1}$ \cdot d $^{-1}$, ip, \times 5 d)及与G1i (1 mg \cdot kg $^{-1}$ \cdot d $^{-1}$, ig, \times 5 d)联用对实验性糖尿病大鼠空腹血糖、血浆胰岛素、胰岛素敏感性指数、肝糖原及CYP3A活性的影响。免疫组化方法观察胰岛及B细胞形态结构变化,定量分析胰岛素表达水平。结果与模型组相比,DG与G1i联用比单用G1i进一步降低空腹血糖,上调胰岛素及肝糖原水平。DG单用或联用G1i均抑制CYP3A活性并下调肝损伤指标。DG联用G1i时,随CYP3A活性下降,胰岛素及空腹血糖下降率均提高。免疫组化显示,DG可进一步改善G1i对胰岛及B细胞形态结构的影响,并使胰岛素分泌增加。结论 DG可增强G1i降糖效应,其机制可能与其抑制CYP3A活性,使G1i代谢延缓,致使降糖效应增强并与其促进胰岛B细胞修复和再生有关,提示DG有作为口服降糖药辅助用药的可能性。

 关键词
 糖尿病, 实验性
 18 α-甘草酸二铵
 格列本脲
 药物协同作用
 血糖
 胰岛素
 细胞色素P450 CYP3A

 肝功能试验

分类号 R977.15

Mechanism of combined action of 18 α -diammonii glycyrrhizinatis and glibenclamide on glucose metabolism in experimental diabetic rats

CHEN Jie, PENG Ren-Xiu*, YANG Jing, LU Jing-Feng

(Department of Pharmacology, Medical College, Wuhan University, Wuhan 430071, China)

Abstract

AIM To investigate whether 18 α-diammonii glycyrrhizinatis(DG) influences the metabolism and hypoglycemic effect of glibenclamide(Gli), their combined action and mechanism. METHODS DG(25 mg·kg⁻¹·d⁻¹, ip) and/or Gli(1 mg·kg⁻¹·d⁻¹, ig) were given to the alloxan(150 mg·kg⁻¹, ip)induced diabetic rats for 5 consecutive days. The fasting plasma glucose(FPG), plasma insulin, insulin sensitivity index (ISI), hepatin and the activities of CYP3A were measured. Pathological morphology of pancreatic islets and B cell and the expression of insulin were investigated by immunohistochemical method and image analysis. The markers of liver injury were also observed. RESULTS Treated with Gli, FPG reduced by 28%, insulin and hepatin increased by 65% and 64%, respectively, as compared with model group. Treated with DG+Gli, FPG reduced by 69%, insulin and hepatin increased by 172% and 179% as compared with model group, which were significantly different from Gli-treated group. The activities of CYP3A and the markers of liver injury significantly decreased in rats treated with DG and DG+Gli. The activities of CYP3A were negatively correlated with insulin and the reduction rate of FPG in rats treated with DG+Gli. The results of immunohistochemistry showed that DG could potentiate the effect of Gli on the pathological morphology of pancreatic islets and B cell and the intensities of positive immunostaining for insulin. CONCLUSION DG potentiates the hypoglycemic effect of Gli, which may be associated with the inhibition of the activities of CYP3A and promoting the repair and regeneration of the damaged islet B cell. The results suggest that DG has the possibility to be used as an adjuvant drug of oral hypoglycemic agents.

 Key words
 diabetes mellitus
 experimental
 18 α-diammonii glycyrrhizinatis
 glibenclamide
 drug

 synergism
 blood glucose
 insulin
 cytochrome P-450 CYP3A
 liver function tests

DOI:

扩展功能

本文信息

- ▶ Supporting info
- ▶ **PDF**(400KB)
- ▶[HTML全文](0KB)
- ▶参考文献

服务与反馈

- ▶把本文推荐给朋友
- ▶加入我的书架
- ▶加入引用管理器
- ▶复制索引
- ▶ Email Alert
- ▶文章反馈
- ▶浏览反馈信息

相关信息

▶ <u>本刊中 包含"糖尿病,实验性"的</u> 相关文章

▶本文作者相关文章

- · <u>陈 洁</u>
- 彭仁琇
- 杨静
- 吕靖峰